Clinical study
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial**

https://doi.org/10.1016/S0002-9343(96)00227-6Get rights and content

Abstract

Purpose

The potent bisphosphonates offer great promise in the management of Paget's disease of bone, but are currently available only as parenteral preparations in most countries. There is a need for a well-tolerated, oral therapy. Furthermore, none of the currently available therapies have been rigorously demonstrated to heal the lytic bone lesions characteristic of this condition. Alendronate is a potent new oral aminobisphosphonate that has shown promising effects on Paget's disease in preliminary studies.

Methods

We report a double-blind, randomized comparison of oral alendronate 40 mg/day and placebo over 6 months in 55 patients with Pagef s disease. Efficacy was determined from measurements of biochemical indices of bone turnover (serum alkaline phosphatase and urine N-telopeptide) and blinded radiologic assessment of lytic bone lesions.

Results

N-telopeptide excretion declined by 86% and serum alkaline phosphatase by 73% in patients receiving alendronate, but remained stable in patients receiving placebo (P < 0.001 between groups for both indices). Responses were similar whether or not patients had previously received bisphosphonate treatment. Alendronate treatment normalized alkaline phosphatase in 48% of patients. Forty-eight percent of alendronate-treated patients showed radiologic improvement in osteolysis whereas in the placebo group only 4% improved (P = 0.02 for between-groups comparison). No patient in either group showed worsening of osteolysis. Bone histomorphometry indicated that alendronate tended to normalize turnover indices. There was no evidence of abnormal mineralization in bone biopsies taken from 12 alendronate-treated subjects. The treatment was well tolerated.

Conclusion

Oral alendronate appears to be a safe and effective therapy for Paget's disease and results in healing of lytic bone lesions.

References (24)

  • AdamiS et al.

    Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate

    Calcif Tissue int

    (1986)
  • CleelandCS

    Assessment of pain in cancer

    Adv Pain Res Ther

    (1970)
  • Cited by (163)

    • Endocrinology of Bone and Growth Disorders

      2022, Comprehensive Pharmacology
    • Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

      2021, Seminars in Cancer Biology
      Citation Excerpt :

      For instance, increasing doses of alendronate reduced urinary excretion of hydroxyproline, a biochemical marker of collagen degradation, in patients with Paget’s disease [23]. Other pharmacodynamic biochemical biomarkers of bone turnover (serum alkaline phosphatase and urine N-telopeptide) also declined and radiological assessment of lytic bone lesions improved after alendronate treatment [32]. The bone anti-resorptive effects of bisphosphonates in osteoporosis suggest that they may also be efficacious in treating osteolysis associated with multiple myeloma and cancers that metastasize to the bone and related complications such as hypercalcemia.

    • Bisphosphonates—much more than only drugs for bone diseases

      2020, European Journal of Pharmacology
      Citation Excerpt :

      It was also well tolerated and remained in the bones for a long time (Harinck et al., 1987). The comparative trials with the use of placebo and etidronate as a reference drug showed that alendronate was highly effective in the normalization of the level of ALP in 60–70% of patients (Reid et al., 1996; Siris et al., 1996). Another important observation of the trials with alendronate treatment was a persistent biochemical response to this drug.

    • Paget's disease of bone

      2018, Orthopaedics and Trauma
    View all citing articles on Scopus
    **

    This study was supported by grants from Merck Research Laboratories.

    View full text